| Description | Quisovalimab (AVTX-002; AEVI 002; SAR 252067), a human monoclonal antibody targeting LIGHT, a tumor necrosis factor (TNF)-related cytokine (TNFSF14), is crucial for managing acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS) in COVID-19. This compound has potential applications in treating ARDS related to COVID-19 and is subject to ongoing research [1]. |
| molecular weight | N/A |
| CAS | 2427667-03-4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 years | Shipping with blue ice. |